TNFRSF13C and plasma cell myeloma: BAFF-R-based CAR T cells, as compared to benchmark 4-1BB- and CD28-based CAR T cells, exhibited equivalent efficacy in a mouse model of mesothelioma and superior efficacy in a model of multiple myeloma.